USFDA finds procedural lapses at Wockhardts US facility

The quality control unit lacks authority to review production records to assure no errors occurred and fully investigate errors that have occurred, it further said. The FDA has already issued warning letters to two of the Wockhardt's plants in India.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney
moneycontrol.com

Home » News » Business

Jun 04, 2014, 10.24 AM | Source: PTI

USFDA finds procedural lapses at Wockhardt's US facility

The quality control unit lacks authority to review production records to assure no errors occurred and fully investigate errors that have occurred, it further said. The FDA has already issued warning letters to two of the Wockhardt's plants in India.

Like this story, share it with millions of investors on M3

USFDA finds procedural lapses at Wockhardts US facility

The quality control unit lacks authority to review production records to assure no errors occurred and fully investigate errors that have occurred, it further said. The FDA has already issued warning letters to two of the Wockhardt's plants in India.

Post Your Comments

Share Cancel

USFDA finds procedural lapses at Wockhardts US facility
The US Food and Drug Administration has found as many as 12 procedural lapses in drug maker Wockhardt 's US facility in Illinois. The inspection, which was carried out by the FDA officials between January 22 and March 26 this year, pointed out that the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

"There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or the batch has already been distributed," the report said in one of the observations.

The quality control unit lacks authority to review production records to assure no errors occurred and fully investigate errors that have occurred, it further said. The FDA has already issued warning letters to two of the Wockhardt's plants in India.

In November last year, the FDA issued an import alert, effectively a ban, against Wockhardt's Chikalthana plant in western India.

The FDA had imposed a ban on the company's Waluj plant in May.

Wockhardt's Managing Director Murtaza Khorakiwala recently told analysts that FDA had in March inspected the company's Chicago-based Morton Grove Pharmaceuticals unit, which accounts for more than 50 percent of its sales in the United States.

The building used in the manufacture, processing, packing and holding of drug products are not maintained in a clean and sanitary condition, besides the production personnel were not practicing good sanitation and health habits, the reports further observed.

When contacted a company spokesperson declined to comment. Shares of Wockhardt closed at Rs 595.15 apiece, down 3.11 percent on BSE from its previous close.

Buy, Hold, Sell ? Hear it first on M3
USFDA finds procedural lapses at Wockhardts US facility

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login